Additionally, a synthetic peptide inhibitor derived from the synergy region of fibronectin that binds to α5β1 and αvβ3 integrins (ATN-161, also called PHSCN) reduces both MDA-MB-231 breast cancer bone metastasis formation and skeletal tumor outgrowth [14, 16]. Here, FN1 is linked to breast carcinoma.